Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gross

Showing results (101-110 of 148) with videos related to

Pageof 15
Sort By:
Matrix Biology Plus|March 15, 2021
A glycine substitution in the collagenous domain of Col4a3 in mice recapitulates late onset Alport syndromeChristoforos Odiatis, Isavella Savva, Myrtani Pieri, et al.
Genes|September 28, 2023
Genetic Modifiers of Mendelian Monogenic Collagen IV Nephropathies in Humans and MiceConstantinos Deltas, Gregory Papagregoriou, Stavroula F Louka, et al.
BMC Infectious Diseases|August 2, 2023
Indwelling catheter vs intermittent catheterization: is there a difference in UTI susceptibility?Vera Neumeier, Fabian P Stangl, Joëlle Borer, et al.
Pediatric Nephrology (Berlin, Germany)|November 22, 2025
High adherence to angiotensin-converting enzyme inhibitor in children and adolescents with Alport syndrome: objective verification using liquid chromatography-mass spectrometryJan Boeckhaus, Burkhard Tönshoff, Lutz T Weber, et al.
Journal of the American Society of Nephrology : JASN|July 10, 2023
Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- MiceZhihui Zhu, Karoline A T Rosenkranz, Yoshihiro Kusunoki, et al.
Cells|February 25, 2022
Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse ModelsDiana Rubel, Joseph Boulanger, Florin Craciun, et al.
BJU International|March 12, 2025
Similar artefact susceptibility for water- and air-filled urodynamic systems: a non-inferiority randomised controlled trialMadlen M E Kasten, Oliver Gross, Marian S Wettstein, et al.
Pediatric Nephrology (Berlin, Germany)|July 11, 2018
Expert consensus guidelines for the genetic diagnosis of Alport syndromeJudy Savige, Francesca Ariani, Francesca Mari, et al.
Journal of the American Society of Nephrology : JASN|October 19, 2017
Effects of Two Immunosuppressive Treatment Protocols for IgA NephropathyThomas Rauen, Christina Fitzner, Frank Eitner, et al.
The New England Journal of Medicine|December 3, 2015
Intensive Supportive Care plus Immunosuppression in IgA NephropathyThomas Rauen, Frank Eitner, Christina Fitzner, et al.
Pageof 15

Showing results (101-110 of 148) with videos related to

Sort By:
Pageof 15
Matrix Biology Plus|March 15, 2021
A glycine substitution in the collagenous domain of Col4a3 in mice recapitulates late onset Alport syndromeChristoforos Odiatis, Isavella Savva, Myrtani Pieri, et al.
Genes|September 28, 2023
Genetic Modifiers of Mendelian Monogenic Collagen IV Nephropathies in Humans and MiceConstantinos Deltas, Gregory Papagregoriou, Stavroula F Louka, et al.
BMC Infectious Diseases|August 2, 2023
Indwelling catheter vs intermittent catheterization: is there a difference in UTI susceptibility?Vera Neumeier, Fabian P Stangl, Joëlle Borer, et al.
Pediatric Nephrology (Berlin, Germany)|November 22, 2025
High adherence to angiotensin-converting enzyme inhibitor in children and adolescents with Alport syndrome: objective verification using liquid chromatography-mass spectrometryJan Boeckhaus, Burkhard Tönshoff, Lutz T Weber, et al.
Journal of the American Society of Nephrology : JASN|July 10, 2023
Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- MiceZhihui Zhu, Karoline A T Rosenkranz, Yoshihiro Kusunoki, et al.
Cells|February 25, 2022
Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse ModelsDiana Rubel, Joseph Boulanger, Florin Craciun, et al.
BJU International|March 12, 2025
Similar artefact susceptibility for water- and air-filled urodynamic systems: a non-inferiority randomised controlled trialMadlen M E Kasten, Oliver Gross, Marian S Wettstein, et al.
Pediatric Nephrology (Berlin, Germany)|July 11, 2018
Expert consensus guidelines for the genetic diagnosis of Alport syndromeJudy Savige, Francesca Ariani, Francesca Mari, et al.
Journal of the American Society of Nephrology : JASN|October 19, 2017
Effects of Two Immunosuppressive Treatment Protocols for IgA NephropathyThomas Rauen, Christina Fitzner, Frank Eitner, et al.
The New England Journal of Medicine|December 3, 2015
Intensive Supportive Care plus Immunosuppression in IgA NephropathyThomas Rauen, Frank Eitner, Christina Fitzner, et al.
Pageof 15